Chewed Versus Integral Pill of Ticagrelor

• Status: Active, not recruiting
• Trial end date: 2021-07-31
• Target enrollment: 0
• Participant gender: All

Summary

Hypothesis The primary question the investigators propose to answer is whether all patients undergoing PCI with stent deployment who receive chewed ticagrelor will demonstrate more rapid drug absorption and decreased platelet reactivity as compared to integral pill form 1 hour after drug administration.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aurora Health Care
• Treatments: Ticagrelor

Criteria

Inclusion Criteria:

• All patients presenting to the cardiac catheterization lab for percutaneous coronary intervention.

Exclusion Criteria:

• Age <18 years or Age >89 years

• Known coagulopathy, bleeding diathesis, or active bleeding

• History of recent gastrointestinal or genitourinary bleed within 2 months

• Known chronic therapy with clopidogrel, prasugrel, or ticagrelor

• Major surgery within last 6 weeks

• History of intracranial bleed or intracranial neoplasm

• Suspected aortic dissection

• Severe hemodynamic instability, cardiogenic shock

• Life expectancy <1 year

• Known severe liver or renal disease

• Known HIV treatment

• Any use of GP IIb-IIIa inhibitors 48-hours before the procedure or any use during the procedure

• Any use of Cangrelor during or after the procedure

• Hemoglobin <10 g/dL, PLT <100x10^9/L

• Pregnancy

• Known allergy to study medication